This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ResMed Management Discusses Q4 2012 Results - Earnings Call Transcript

Accessories also grew strongly, as both large and small HMEs and DMEs are becoming more systematic about resupply and delivery of replenishment supplies to the patients who need them.

Our global growth in Flow Generators this quarter was primarily driven by the high-end devices. Strong sales reflect the benefits of having all of our PAP devices configured on the smaller, quieter and more appealing S9 platform.

In the Americas the S9 AutoSet and the VPAP Adapt, which is an adaptive servo-ventilator did particularly well.

Growth in the Flow Generator segment was also driven by a positive mix shift from basic CPAP to APAP due to the ongoing growth of home sleep testing, as well as, we believe, physician preference to put patients on the AutoSet, which provides more flexible therapy, improves patient comfort and appears to enhance compliance.

The new EasyCare Online Compliance Management system continues to be well received, and we expect to see some solid ongoing uptake from existing, as well as new accounts.

Products and programs which provide superior therapy and better compliance are what bring the most value to the patients, customers and service providers. In other words, across the whole food chain.

Europe continues to be challenging due to difficult macroeconomic environment, although sales were relatively strong in both Germany and the U.K. Despite this challenging economic climate, bilevel, AutoSets CS, which is also our version of the adaptive servo-ventilator in the rest of the world, and the Stellar products all did well in this quarter.

We also believe that great opportunities exist in Europe to address the connection between sleep-disordered breathing and various comorbidities, such as heart disease, diabetes and so on, as well as occupational health and the more compelling economic case and the more -- and the more and more compelling economic case for treating sleep apnea in general.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs